{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:27:46Z","timestamp":1778621266585,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1756-8722-6-79","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T00:19:24Z","timestamp":1382487564000},"source":"Crossref","is-referenced-by-count":53,"title":["Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing"],"prefix":"10.1186","volume":"6","author":[{"given":"Ruben A","family":"Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"350_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ajh.23169","volume":"87","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A: Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012, 87: 562-568. 10.1002\/ajh.23169.","journal-title":"Am J Hematol"},{"key":"350_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","volume":"35","author":"RA Mesa","year":"2011","unstructured":"Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP: MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011, 35: 12-13. 10.1016\/j.leukres.2010.07.019.","journal-title":"Leuk Res"},{"key":"350_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","volume":"60","author":"OI Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab OI, Levine RL: Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009, 60: 233-245. 10.1146\/annurev.med.60.041707.160528.","journal-title":"Annu Rev Med"},{"key":"350_CR4","first-page":"1","volume":"9","author":"SA Gregory","year":"2011","unstructured":"Gregory SA, Mesa RA, Hoffman R, Shammo JM: Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011, 9: 1-16.","journal-title":"Clin Adv Hematol Oncol"},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A: Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011, 29: 1356-1363. 10.1200\/JCO.2010.32.9490.","journal-title":"J Clin Oncol"},{"key":"350_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","volume":"130","author":"KE Panteli","year":"2005","unstructured":"Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, Bourantas KL: Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005, 130: 709-715. 10.1111\/j.1365-2141.2005.05674.x.","journal-title":"Br J Haematol"},{"key":"350_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.exphem.2006.07.004","volume":"34","author":"JC Wang","year":"2006","unstructured":"Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J: Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol. 2006, 34: 1617-1623. 10.1016\/j.exphem.2006.07.004.","journal-title":"Exp Hematol"},{"key":"350_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quint\u00e1s-Cardama","year":"2011","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J, Verstovsek S: Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011, 10: 127-140. 10.1038\/nrd3264.","journal-title":"Nat Rev Drug Discov"},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","volume":"2011","author":"NC Cross","year":"2011","unstructured":"Cross NC: Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011, 2011: 208-214. 10.1182\/asheducation-2011.1.208.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"350_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1586\/ehm.10.28","volume":"3","author":"ST Oh","year":"2010","unstructured":"Oh ST, Gotlib J: JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010, 3: 323-337. 10.1586\/ehm.10.28.","journal-title":"Expert Rev Hematol"},{"key":"350_CR11","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.2174\/092986712803251511","volume":"19","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Mughal TI, Verstovsek S: Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012, 19: 4399-4413. 10.2174\/092986712803251511.","journal-title":"Curr Med Chem"},{"key":"350_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.2174\/187152012803529727","volume":"12","author":"FP Santos","year":"2012","unstructured":"Santos FP, Verstovsek S: JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?. Anticancer Agents Med Chem. 2012, 12: 1098-1109. 10.2174\/187152012803529727.","journal-title":"Anticancer Agents Med Chem"},{"key":"350_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1756-8722-5-43","volume":"5","author":"J Randhawa","year":"2012","unstructured":"Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S: Splenomegaly in myelofibrosis\u2013new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012, 5: 43-10.1186\/1756-8722-5-43.","journal-title":"J Hematol Oncol"},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3109\/10428194.2012.710905","volume":"54","author":"RA Mesa","year":"2013","unstructured":"Mesa RA: The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma. 2013, 54: 242-251. 10.3109\/10428194.2012.710905.","journal-title":"Leuk Lymphoma"},{"key":"350_CR15","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S: Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010, 115: 3109-3117. 10.1182\/blood-2009-04-214957.","journal-title":"Blood"},{"key":"350_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012, 366: 799-807. 10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"key":"350_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012, 366: 787-798. 10.1056\/NEJMoa1110556.","journal-title":"N Engl J Med"},{"key":"350_CR18","volume-title":"J Hematol Oncol","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg S, Prchal JT, Jamieson K, Terebelo H, Ortega G, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor VA, Levy RS, Kantarjian HM, Verstovsek S: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013, in press"},{"key":"350_CR19","volume-title":"Haematologica","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013, Epub ahead of print"},{"key":"350_CR20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V120.21.801.801","volume":"120","author":"F Cervantes","year":"2012","unstructured":"Cervantes F, Kiladjian J-J, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Gisslinger H, Vannucchi AM, Knoops L, Harrison CN: Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract]. Blood. 2012, 120: 801-","journal-title":"Blood"},{"key":"350_CR21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010, 363: 1117-1127. 10.1056\/NEJMoa1002028.","journal-title":"N Engl J Med"},{"key":"350_CR22","first-page":"1","volume":"6","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian H, Mesa RA: Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013, 6: 1-9.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"350_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12325-011-0024-2","volume":"28","author":"L San Miguel Amigo","year":"2011","unstructured":"San Miguel Amigo L, Franco Osorio R, Mercadal Vilchez S, Martinez-Frances A: Azacitidine adverse effects in patients with myelodysplastic syndromes. Adv Ther. 2011, 28 (4): 6-11.","journal-title":"Adv Ther"},{"key":"350_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005, 352: 549-557. 10.1056\/NEJMoa041668.","journal-title":"N Engl J Med"},{"key":"350_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00277-008-0449-0","volume":"87","author":"A Giagounidis","year":"2008","unstructured":"Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA: Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol. 2008, 87: 345-352. 10.1007\/s00277-008-0449-0.","journal-title":"Ann Hematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T11:45:08Z","timestamp":1596714308000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-6-79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-6-79","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,22]]},"article-number":"79"}}